Market Cap 7.14B
Revenue (ttm) 36.13M
Net Income (ttm) -215.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -595.99%
Debt to Equity Ratio 0.00
Volume 2,507,000
Avg Vol 2,476,150
Day's Range N/A - N/A
Shares Out 75.63M
Stochastic %K 74%
Beta 1.26
Analysts Sell
Price Target $95.77

Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cel...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 30 253 8800
Address:
Uppsalalaan 17, 3rd & 4th floor, Utrecht, Netherlands
Bullish_Trader555
Bullish_Trader555 Oct. 24 at 2:44 PM
0 · Reply
Bullish_Trader555
Bullish_Trader555 Oct. 24 at 2:09 PM
$MRUS Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety – 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) - $SPY $LLY $REGN
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 21 at 5:34 PM
@outlawinvestor1 FYI $MRUS filed their 14D9 this morning that includes, among other things, the revenue forecast provided $GMAB as part of the broader financial projections. You were definitely right again. The MRUS forecasts, especially in the later years, are considerably higher than 3 analysts had projected. I prepared a simple comparison of the 2 showing you snapshots as well. We track these for all commercial-stage bios. It's our experience the projections are closer except for BPMC (BPMC's forecasts were much higher than analysts in the later years). I included an updated comparison of the various revenue multiples versus $PTGX as well. For those interested in clinical-stage bios (and commercial-stage for that matter), may I recommend you follow outlawinvestor1 Otherwise FYI only. This is not investment advice. $IBB $IBBQ
0 · Reply
Quantumup
Quantumup Oct. 20 at 7:30 PM
Piper Sandler⬆️ $CRBP's PT to $51 from $35, reiterated at Overweight, and said Data Provides Proof of Efficacy for CRB-701 in HNSCC and Cervical $MRUS - $GMAB $PFE Piper Sandler added:
0 · Reply
Quantumup
Quantumup Oct. 20 at 11:17 AM
H.C. Wainwright reiterated $CRBP Buy/$40 after Corbus presented Phase 1/2 data of CRB-701 at ESMO 2025 and hosted a panel of KOL to discuss CRB-701 in HNSCC. $PFE $MRUS H.C. Wainwright said in its note:
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 17 at 6:58 PM
@outlawinvestor1 Sean I know little about $PRAX except they raised $525MM from investors after publishing the data yesterday. That is an enormous number in any market. Attached is a comparison of PRAX's valuation versus $MRUS & $PTGX using analyst consensus as of yesterday (before the data was published), as of today excluding the most aggressive forecast and "consensus" that includes the most aggressive forecast. You see PRAX trades at a much lower multiple since revenues are not forecast for some time. Seems to me PRAX is a value should they move forward but I otherwise dislike clinical-stage bio & was hoping you'd take a quick look...or any investor familiar with PRAX. This is not investment advice. $IBB $IBBQ
2 · Reply
Power2k
Power2k Oct. 14 at 3:23 PM
$PYXS $GMAB acquired $MRUS for 8B mostly due to Merus' promising Head & Neck cancer (HNSCC) trial data. Pyxis has a matched or even a bit superior HNSCC data than Merus', and it sits only at 200M cap. Extremely undervalued.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 13 at 4:22 PM
$MRUS Merus Reveals Petosemtamab In Metastatic Colorectal Cancer Abstract Selected For Plenary Session Oral Presentation At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics, Being Held In Boston, Massachusetts On October 22-26, 2025
0 · Reply
ZacksResearch
ZacksResearch Oct. 6 at 3:00 PM
$GMAB spikes 21.9% after announcing $8B acquisition of $MRUS! Strategic acquisition to expand GMAB's oncology pipeline, adding Merus' promising late-stage candidate, petosemtamab. Petosemtamab has FDA Breakthrough Therapy designations and impressive phase II results, supporting GMAB's long-term growth strategy. Discover why GMAB could be a biotech leader 👉 https://www.zacks.com/stock/news/2762765/gmab-stock-soars-219-in-a-month-following-mrus-acquisition-deal?cid=sm-stocktwits-2-2762765-body-14729&ADID=SYND_STOCKTWITS_TWEET_2_2762765_BODY_14729
0 · Reply
SolarEdge2445
SolarEdge2445 Oct. 3 at 6:01 PM
$MRUS NXXT fundamentals loud but price still shy 🙈 once mkt catches up it ain’t tradin in 1s no more
0 · Reply
Latest News on MRUS
Genmab to buy Dutch cancer drugmaker Merus for $8 billion

Sep 29, 2025, 1:19 AM EDT - 26 days ago

Genmab to buy Dutch cancer drugmaker Merus for $8 billion

GMAB


Merus to Present at the 2025 Wells Fargo Healthcare Conference

Aug 28, 2025, 8:00 AM EDT - 2 months ago

Merus to Present at the 2025 Wells Fargo Healthcare Conference


Merus N.V. Announces Pricing of Public Offering of Common Shares

Jun 4, 2025, 12:13 AM EDT - 5 months ago

Merus N.V. Announces Pricing of Public Offering of Common Shares


Merus N.V. Announces Proposed Public Offering of Common Shares

Jun 3, 2025, 4:05 PM EDT - 5 months ago

Merus N.V. Announces Proposed Public Offering of Common Shares


Merus to Present at Upcoming Investor Conferences

May 27, 2025, 8:00 AM EDT - 5 months ago

Merus to Present at Upcoming Investor Conferences


Merus to Present at BofA Securities 2025 Health Care Conference

May 8, 2025, 8:00 AM EDT - 6 months ago

Merus to Present at BofA Securities 2025 Health Care Conference


Merus: Riding The Bispecific Wave In Oncology

Apr 7, 2025, 4:34 AM EDT - 7 months ago

Merus: Riding The Bispecific Wave In Oncology


Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff

Jan 20, 2025, 5:08 AM EST - 9 months ago

Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff


Merus Scores Its First FDA Approval For Lung Cancer Drug

Dec 5, 2024, 2:49 PM EST - 11 months ago

Merus Scores Its First FDA Approval For Lung Cancer Drug


US FDA approves Merus' therapy to treat lung, pancreatic cancers

Dec 4, 2024, 3:48 PM EST - 11 months ago

US FDA approves Merus' therapy to treat lung, pancreatic cancers


Merus Receives FDA extension of PDUFA for zenocutuzumab

Nov 5, 2024, 6:30 AM EST - 1 year ago

Merus Receives FDA extension of PDUFA for zenocutuzumab


Merus: Great European Oncology Developer, But Properly Valued

Aug 14, 2024, 5:13 PM EDT - 1 year ago

Merus: Great European Oncology Developer, But Properly Valued


Bullish_Trader555
Bullish_Trader555 Oct. 24 at 2:44 PM
0 · Reply
Bullish_Trader555
Bullish_Trader555 Oct. 24 at 2:09 PM
$MRUS Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety – 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) - $SPY $LLY $REGN
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 21 at 5:34 PM
@outlawinvestor1 FYI $MRUS filed their 14D9 this morning that includes, among other things, the revenue forecast provided $GMAB as part of the broader financial projections. You were definitely right again. The MRUS forecasts, especially in the later years, are considerably higher than 3 analysts had projected. I prepared a simple comparison of the 2 showing you snapshots as well. We track these for all commercial-stage bios. It's our experience the projections are closer except for BPMC (BPMC's forecasts were much higher than analysts in the later years). I included an updated comparison of the various revenue multiples versus $PTGX as well. For those interested in clinical-stage bios (and commercial-stage for that matter), may I recommend you follow outlawinvestor1 Otherwise FYI only. This is not investment advice. $IBB $IBBQ
0 · Reply
Quantumup
Quantumup Oct. 20 at 7:30 PM
Piper Sandler⬆️ $CRBP's PT to $51 from $35, reiterated at Overweight, and said Data Provides Proof of Efficacy for CRB-701 in HNSCC and Cervical $MRUS - $GMAB $PFE Piper Sandler added:
0 · Reply
Quantumup
Quantumup Oct. 20 at 11:17 AM
H.C. Wainwright reiterated $CRBP Buy/$40 after Corbus presented Phase 1/2 data of CRB-701 at ESMO 2025 and hosted a panel of KOL to discuss CRB-701 in HNSCC. $PFE $MRUS H.C. Wainwright said in its note:
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 17 at 6:58 PM
@outlawinvestor1 Sean I know little about $PRAX except they raised $525MM from investors after publishing the data yesterday. That is an enormous number in any market. Attached is a comparison of PRAX's valuation versus $MRUS & $PTGX using analyst consensus as of yesterday (before the data was published), as of today excluding the most aggressive forecast and "consensus" that includes the most aggressive forecast. You see PRAX trades at a much lower multiple since revenues are not forecast for some time. Seems to me PRAX is a value should they move forward but I otherwise dislike clinical-stage bio & was hoping you'd take a quick look...or any investor familiar with PRAX. This is not investment advice. $IBB $IBBQ
2 · Reply
Power2k
Power2k Oct. 14 at 3:23 PM
$PYXS $GMAB acquired $MRUS for 8B mostly due to Merus' promising Head & Neck cancer (HNSCC) trial data. Pyxis has a matched or even a bit superior HNSCC data than Merus', and it sits only at 200M cap. Extremely undervalued.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 13 at 4:22 PM
$MRUS Merus Reveals Petosemtamab In Metastatic Colorectal Cancer Abstract Selected For Plenary Session Oral Presentation At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics, Being Held In Boston, Massachusetts On October 22-26, 2025
0 · Reply
ZacksResearch
ZacksResearch Oct. 6 at 3:00 PM
$GMAB spikes 21.9% after announcing $8B acquisition of $MRUS! Strategic acquisition to expand GMAB's oncology pipeline, adding Merus' promising late-stage candidate, petosemtamab. Petosemtamab has FDA Breakthrough Therapy designations and impressive phase II results, supporting GMAB's long-term growth strategy. Discover why GMAB could be a biotech leader 👉 https://www.zacks.com/stock/news/2762765/gmab-stock-soars-219-in-a-month-following-mrus-acquisition-deal?cid=sm-stocktwits-2-2762765-body-14729&ADID=SYND_STOCKTWITS_TWEET_2_2762765_BODY_14729
0 · Reply
SolarEdge2445
SolarEdge2445 Oct. 3 at 6:01 PM
$MRUS NXXT fundamentals loud but price still shy 🙈 once mkt catches up it ain’t tradin in 1s no more
0 · Reply
PhaseTrack_10
PhaseTrack_10 Oct. 2 at 4:41 PM
$MRUS Accumulated SHOT between $0.275 and $0.285 with volume confirmation. My plan sells 25 percent at $0.31 and reloads on $0.295. Momentum strategy targets $0.33 if buyers sustain pressure.
0 · Reply
SilverOakCapitalX
SilverOakCapitalX Oct. 2 at 4:33 PM
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 2:42 AM
$MRUS: Unusual Options Activity Alerted PUT flow observed 175x contracts at Strike price of $90 Exp on 01/16/2026 with Premium of $35K and showing BEARISH Sentiment
0 · Reply
ShiftTone_78
ShiftTone_78 Oct. 1 at 7:54 PM
$MRUS SHOT coiling tight with 0.2797 last and 0.2849 high on deck gives a clean 0.015 to 0.020 upside window while volume sits at 6,410,746 and momentum funds position for a run into 0.3000 if BONK extends 🔥
0 · Reply
urie1l_foster
urie1l_foster Oct. 1 at 5:35 PM
0 · Reply
TickHawkX2
TickHawkX2 Oct. 1 at 5:13 PM
$MRUS SHOT float small short interest 1 to 2% is enough when borrow tight supply shock triggers SR squeeze 20 to 40% intraday candles possible tape tells the story level 2 confirms
0 · Reply
Power2k
Power2k Oct. 1 at 5:10 PM
$IMRX I dived deeply down to check the two gold-standards of Oncology Studies - Median Overall Survival (mOS) and Median Progression-Free Survival (mPFS) between $MRUS 's Bizengri and Immuneering's Atebimetinib + mGnP. The Phase 2 data published in The New England Journal of Medicine shows that the mPFS for Bizengri was 6.8 months, and its mOS for non-small-cell lung cancer (NSCLC) was 14.9 months. In sharp contrast, IMRX's recent Phase 2 data in 1L pancreatic cancer showed mPFS for Atebimetinib + mGnP is 9.6 months, and although mOS data is not matured enough yet, the predicted mOS will be at least 24-27 months, which largely beating Bizengri's data by light years. On Dec 4, 2024, the FDA granted accelerated approval to Bizengri. My point is as OS gets matured enough for mOS calculation (about 8-12 months away), IMRX can definitely apply for accelerated approval at that point at least get Atebi for passionate use as this is definitely going to save lives of pancreatic cancer patients.
0 · Reply
VectorGrid_71
VectorGrid_71 Oct. 1 at 4:58 PM
$MRUS SHOT basing above prior pivot with bids stacking around 0.68 and 0.72. If price clears 0.80 then 0.95 and 1.05 open fast. Simple 1 to 3 R setup with tight risk.
0 · Reply
Power2k
Power2k Oct. 1 at 3:17 PM
$IMRX The boldest prediction I came across on X: "You ready? Bizengri by $MRUS was in Phase 2 last fall. After Merus & Bizengri reported their 86% survival rate, the FDA immediately granted "Accelerated Approval" to Merus, allowing them to fully bypass Ph 3 and go directly to commercialization. Immuneering is at Phase 2 too and got exactly the same OS of 86% for pancreatic cancer but with much much less side effects. This recent $200 mil capital raise ($175 M offering + $25 M from $SNY) for IMRX? It is NOT for Phase 3. It is for complete commercialization in Jan 2026 (after accelerated approval)"
1 · Reply
Bornjever
Bornjever Oct. 1 at 2:58 PM
$LEGN $MRUS $SNDX $URGN $ZYME yes LEGN is especially hot since going down nicely but do not forget ARQT as earn coming end of October.
1 · Reply
anachartanalyst
anachartanalyst Sep. 30 at 6:02 PM
$MRUS https://anachart.com/wp-content/uploads/ana_temp/1759255334_soc-img.jpg
0 · Reply
tyle4r_wang
tyle4r_wang Sep. 30 at 6:01 PM
$MRUS SHOT early birds eating, late crowd chasing .30 😤🚀
0 · Reply